The serine protease inhibitor, PAI-1, which is a major target of the TGF-β1/p53 senescence signalling pathway [30], was elevated in vehicle-treated diabetic mice as compared with NDM CTRL mice; in contrast, the Dasatinib-treated group did not differ from the NDM CTRL or T2DM Vehicle groups (Fig. 6E). This evidence concerns the gene TGFB1 and type 2 diabetes mellitus.